ClinicalTrials.Veeva

Menu

A French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy. (OASIS)

B

BTG

Status

Completed

Conditions

Breast Cancer

Treatments

Procedure: Sentinel lymph node identification
Drug: Technetium (99mTc)
Drug: methylene blue
Drug: indocyanine green

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT06024213
PR024-CLN-pro101

Details and patient eligibility

About

This prospective, observational study will evaluate the patient-based sentinel lymph node detection rate when using the Infracyanine® (indocyanine green) dye technique in patients undergoing surgery for breast cancer.

The study will describe the demographic, clinical, and tumour characteristics of patients with breast cancer undergoing surgery.

The study will describe the characteristics of how the indocyanine green dye technique is used including the dose and volume of dye used, the number and type of injection sites used to give the dye, the equipment used to detect the dye and locate the sentinel lymph node, and whether indocyanine green is used on its own or with other dyes (blue dye and/or 99mTechnetium dye).

The study will evaluate the characteristics of sentinel lymph node biopsy procedures performed using indocyanine green dye including the number of biopsies performed, the time taken to detect the sentinel lymph node and perform the biopsy, and how many sentinel lymph nodes are detected using indocyanine green dye, blue dye, and 99mTechnetium dye.

The study will also assess the safety of using indocyanine green dye for 6 weeks following surgery.

Enrollment

101 patients

Sex

Female

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Female
  • Aged ≥18 years
  • Undergoing breast cancer surgery with an indication for sentinel lymph node biopsy
  • Receiving Infracyanine® (indocyanine green; alone or in combination with blue dye or 99mTc) for intraoperative identification of sentinel lymph node according to the Summary of Product Characteristics

Exclusion criteria

  • Male
  • Pregnant or nursing female
  • Previous allergy to indocyanine green or to any excipients
  • Already included in a surgical trial
  • Patient opposed to collection and processing of their data

Trial contacts and locations

6

Loading...

Central trial contact

Jennie Molland

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems